New data on Stealth's Alexion-partnered asset

Stealth BioTherapeutics (Nasdaq: MITO), a US biotech focused on diseases involving mitochondrial dysfunction, has announced new data on its lead product.

The results are from the open-label extension portion of the Phase II/III TAZPOWER Barth syndrome study evaluating elamipretide, a candidate subject to a co-development and commercialization partnership with Alexion Pharmaceuticals (Nasdaq: ALXN).

"These changes in well-established biomarkers add to the body of evidence we expect to discuss with regulatory authorities over the next several months"These findings showed that treatment with elamipretide resulted in a 27% increase in average cardiac stroke volume, or the amount of blood pumped by the heart's left ventricle per contraction, from the trial baseline to week 36 of the open-label extension.